본문 바로가기
KERD
논문KCI 등재

Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment

이윤주|임경민|아브달아메드|조쌍구|Mohana Devi Subramaniam|Balachandar Vellingiri|Kaavya Jayaramayya|Iyer Mahalaxmi|Neethu Raj|Se Jong Kim|Jong Yub An|Yujin Choi|Arthi Kirubhakaran
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2020.08|BMB Reports|제53권 제8호|pp. 400-412|DOI 10.5483/BMBRep.2020.53.8.121

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

COVID-19TherapyExosomeImmunomodulationMesenchymal stem cells (MSCs)Ongoing Clinical trials
주제분류화학

초록

The world has witnessed unimaginable damage from the coronavirus disease-19 (COVID-19) pandemic. Because the pandemic is growing rapidly, it is important to consider diverse treatment options to effectively treat people worldwide. Since the immune system is at the hub of the infection, it is essential to regulate the dynamic balance in order to prevent the overexaggerated immune responses that subsequently result in multiorgan damage. The use of stem cells as treatment options has gained tremendous momentum in the past decade. The revolutionary measures in science have brought to the world mesenchymal stem cells (MSCs) and MSC-derived exosomes (MSC-Exo) as therapeutic opportunities for various diseases. The MSCs and MSCExos have immunomodulatory functions; they can be used as therapy to strike a balance in the immune cells of patients with COVID-19. In this review, we discuss the basics of the cytokine storm in COVID-19, MSCs, and MSC-derived exosomes and the potential and stem-cell-based ongoing clinical trials forCOVID-19.

Abstract

The world has witnessed unimaginable damage from the coronavirus disease-19 (COVID-19) pandemic. Because the pandemic is growing rapidly, it is important to consider diverse treatment options to effectively treat people worldwide. Since the immune system is at the hub of the infection, it is essential to regulate the dynamic balance in order to prevent the overexaggerated immune responses that subsequently result in multiorgan damage. The use of stem cells as treatment options has gained tremendous momentum in the past decade. The revolutionary measures in science have brought to the world mesenchymal stem cells (MSCs) and MSC-derived exosomes (MSC-Exo) as therapeutic opportunities for various diseases. The MSCs and MSCExos have immunomodulatory functions; they can be used as therapy to strike a balance in the immune cells of patients with COVID-19. In this review, we discuss the basics of the cytokine storm in COVID-19, MSCs, and MSC-derived exosomes and the potential and stem-cell-based ongoing clinical trials forCOVID-19.

참고문헌 (104)

  1. Vellingiri B, "COVID-19 : A promising cure for the global panic", Sci Total Environ, 725, pp.138277~ (2020)
  2. Mahalaxmi Iyer, "COVID-19: an update on diagnostic and therapeutic approaches", BMB Reports, 53(4), pp.191~205 (2020), 생화학분자생물학회[DOI]
  3. Grasselli G, "Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy", JAMA, 323, pp.1574~1581 (2020)
  4. Sun X, "Cytokine storm intervention in the early stages of COVID-19 pneumonia", Cytokine Growth Factor Rev (2020)[DOI]
  5. Balachandar V, "Follow-up studies in COVID-19 recovered patients-is it mandatory?", Sci Total Environ, 729, pp.139021~ (2020)
  6. Taghavi-farahabadi, M, "Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes", Med Hypotheses, 144, pp.109865~ (2020)
  7. Li G, "Coronavirus infections and immune responses", J Med Virol, 92, pp.424~432 (2020)
  8. Qin C, "Dysregulation of immune response in patients with COVID-19 in Wuhan, China", Clin Infect Dis (2020)[DOI]
  9. Wang W, "The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis" (2020)[DOI]
  10. Tufan A, "COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs", Turk J Med Sci, 50, pp.620~632 (2020)
  11. Sakaguchi S, "FOXP3+ regulatory T cells in the human immune system", Nat Rev Immunol, 10, pp.490~500 (2010)
  12. Zbinden‐Foncea H, "Does high cardiorespiratory fitness confer some protection against pro‐inflammatory responses after infection by SARS‐CoV‐2?", Obesity (2020)[DOI]
  13. Shneider A, "Can melatonin reduce the severity of COVID-19 pandemic?", Int Rev Immunol, 39, pp.153~162 (2020)
  14. Guo J, "Coronavirus Disease 2019(COVID-19)and Cardiovascular Disease : A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors", angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection, 2020, pp.9, e016219~
  15. Conti P, "Induction of pro-inflammatory cytokines(IL-1 and IL-6)and lung inflammation by Coronavirus-19(COVI-19 or SARS-CoV-2) : anti-inflammatory strategies", J Biol Regul Homeost Agents, 34, pp.1~ (2020)
  16. Zhao Q, "Mesenchymal stem cells : Immunomodulatory capability and clinical potential in immune diseases", J Cell Immunother, 2, pp.3~20 (2016)
  17. Prockop DJ, "The exciting prospects of new therapies with mesenchymal stromal cells", Cytotherapy, 19, pp.1~8 (2017)
  18. Wilson JG, "Mesenchymal stem(stromal)cells for treatment of ARDS : a phase 1clinical trial", Lancet Respir Med, 3, pp.24~32 (2015)
  19. Uccelli A, "Mesenchymal stem cells in health and disease", Nat Rev Immunol, 8, pp.726~736 (2008)
  20. Ren G, "Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide", Cell Stem Cell, 2, pp.141~150 (2008)
  21. Waterman RS, "A new mesenchymal stem cell(MSC)paradigm : polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype", PLoS One, 5, pp.e10088~ (2010)
  22. Patel SA, "Mesenchymal stem cells protect breast cancer cells through regulatory T cells : role of mesenchymal stem cell-derived TGF-β", J Immunol, 184, pp.5885~5894 (2010)
  23. Raffaghello L, "Human mesenchymal stem cells inhibit neutrophil apoptosis : a model for neutrophil preservation in the bone marrow niche", Stem Cells, 26, pp.151~162 (2008)
  24. Thanunchai M, "Mesenchymal stromal cells and viral infection", Stem Cells Int, 2015, pp.860950~ (2015)
  25. Bari E, "Mesenchymal stromal cell secretome for severe COVID-19 infections : Premises for the therapeutic use", Cells, 9, pp.924~ (2020)
  26. Crivelli B, "Mesenchymal stem", stromal cell extracellular vesicles : From active principle to next generation drug delivery system, 2017, pp.262, 104~117
  27. Deffune E, "Mesenchymal stem cell(MSc)secretome : a possible therapeutic strategy for intensive-care COVID-19 patients", Med Hypotheses, 142, pp.109769~ (2020)
  28. Keshtkar S, "Mesenchymal stem cell-derived extracellular vesicles : novel frontiers in regenerative medicine", Stem Cell Res Ther, 9, pp.63~ (2018)
  29. Guohua Lou, "Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases", Experimental and Molecular Medicine, 49, pp.1~9 (2017), 생화학분자생물학회
  30. Lai P, "A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD", J Hematol Oncol, 11, pp.135~ (2018)
  31. Álvarez V, "The immunomodulatory activity of extracellular vesicles derived from endometrial mesenchymal stem cells on CD4+ T cells is partially mediated by TGFbeta", J Tissue Eng Regen Med, 12, pp.2088~2098 (2018)
  32. Fan Y, "Human fetal liver mesenchymal stem cell-derived exosome impair natural killer cell function", Stem Cells Dev, 28, pp.44~55 (2019)
  33. Domenis R, "Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes", Sci Rep, 8, pp.13325~ (2018)
  34. Song Y, "Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-1β-primed mesenchymal stem cells against sepsis", Stem Cells, 35, pp.1208~1221 (2017)
  35. Chen W, "Immunomodulatory effects of mesenchymal stromal cells-derived exosome", Immunol Res, 64, pp.831~840 (2016)
  36. Ji L, "Comparison of immunomodulatory properties of exosomes derived from bone marrow mesenchymal stem cells and dental pulp stem cells", Immunol Res, 67, pp.432~442 (2019)
  37. He Ping, "AB0291E the effect of human umbilical cord mesenchymal stem cells-derived exosomes on chemokines in collagen-induced arthritis rats", BMJ, pp.1606~1606 (2019)
  38. Mardpour S, "Interaction between mesenchymal stromal cell-derived extracellular vesicles and immune cells by distinct protein content", J Cellular Physiol, 234, pp.8249~8258 (2019)
  39. Baharlooi H, "Mesenchymal stem cell-derived exosomes : A Promising therapeutic ace card to address autoimmune diseases", Int J Stem Cells, 13, pp.13~23 (2020)
  40. Du Y, "Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma", Exp Cell Res, 363, pp.114~120 (2018)
  41. Fujita Y, "Extracellular vesicles in lung microenvironment and pathogenesis", Trends Mol Med, 21, pp.533~542 (2015)
  42. Barani B, "Exosomes : Outlook for future cell-free cardiovascular disease therapy", Adv Exp Med Biol, 2017, pp.285~307 (2017)
  43. Tsuji K, "Secretomes from mesenchymal stem cells against acute kidney injury : possible heterogeneity", Stem Cells Int, 2018, pp.8693137~ (2018)
  44. Khatri M, "Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model", Stem Cell Res Ther, 9, pp.17~ (2018)
  45. Chen J, "Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9)infection, a hint for COVID-19 treatment", Engineering (2020)[DOI]
  46. Vikram S, "Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19", Stem Cells Dev, 29, pp.747~754 (2020)
  47. Leng Z, "Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia", Aging Dis, 11, pp.216~228 (2020)
  48. "Cell Therapy Using Umbilical Cordderived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (STROMA-CoV2) ClinicalTrials.gov Identifier:NCT04333368"[URL]
  49. "Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19. ClinicalTrials.gov Identifier:NCT04428801"[URL]
  50. "A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia. ClinicalTrials.gov Identifier: NCT 04276987"[URL]
  51. "Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells. ClinicalTrials.gov Identifier: NCT04302519"[URL]
  52. "Treatment of Covid-19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells. ClinicalTrials.gov Identifier:NCT04382547"[URL]
  53. "Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019. ClinicalTrials.gov Identifier: NCT04371601"[URL]
  54. "Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19. ClinicalTrials. gov Identifier: NCT04362189"[URL]
  55. "Treatment of COVID-19 patients using Wharton’s Jelly- Mesenchymal Stem Cells. ClinicalTrials. gov Identifier: NCT04313322"[URL]
  56. "Safety and Efficacy study of Allogenic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients. ClinicalTrials.gov Identifier:NCT04336254"[URL]
  57. "NestCell Mesenchymal Stem Cells to Treat Patients with Severe COVID-19 Pneumonia. ClinicalTrials. gov Identifier: NCT04315987"[URL]
  58. "A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19. ClinicalTrials.gov Identifier: NCT04348435"[URL]
  59. "Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19. ClinicalTrials. gov Identifier: NCT04366323"[URL]
  60. "A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19. ClinicalTrials.gov Identifier: NCT04349631"[URL]
  61. "Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19. Clinical-Trials.gov Identifier: NCT04252118"[URL]
  62. "Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)ClinicalTrials.gov Identifier: NCT04288102"[URL]
  63. "Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) ClinicalTrials.gov Identifier: NCT04346368"[URL]
  64. "Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19. ClinicalTrials.gov Identifier: NCT04273646"[URL]
  65. "Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia. ClinicalTrials.gov Identifier: NCT04339660"[URL]
  66. "Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome. ClinicalTrials.gov Identifier: NCT04366063"[URL]
  67. "Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19. ClinicalTrials.gov Identifier: NCT04349540"[URL]
  68. "Use of UC-MSCs for COVID-19 Patients. ClinicalTrials.gov Identifier: NCT04355728"[URL]
  69. "Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19. ClinicalTrials.gov Identifier:NCT04299152"[URL]
  70. "Therapy for Pneumonia Patients Infected by 2019 Novel Coronavirus ClinicalTrials.gov Identifier:NCT04293692"[URL]
  71. "Battle Against COVID-19 Using Mesenchymal Stromal Cells. ClinicalTrials.gov Identifier: NCT 04348461"[URL]
  72. "Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS Clinical-Trials.gov Identifier: NCT04331613"[URL]
  73. "ASC Therapy for Patients With Severe Respiratory COVID-19. ClinicalTrials.gov Identifier: NCT 04341610"[URL]
  74. "Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS). ClinicalTrials.gov Identifier: NCT04377334"[URL]
  75. "Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia. ClinicalTrials.gov Identifier:NCT04269525"[URL]
  76. "MultiStem Administration for COVID-19Induced ARDS (MACoVIA) ClinicalTrials.gov Identifier:NCT04367077"[URL]
  77. "Treatment of Severe COVID-19 Pneumonia with Allogeneic Mesenchymal Stromal Cells (COVID_MSV) Clinical Trials.gov Identifier: NCT04361942"[URL]
  78. "Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease). ClinicalTrials.gov Identifier:NCT04345601"[URL]
  79. "Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)ClinicalTrials.gov Identifier: NCT03042143"[URL]
  80. "Mesenchymal Stem Cell Infusion for COVID-19 Infection. ClinicalTrials.gov Identifier: NCT 04444271"[URL]
  81. "Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19Pneumonia (CELMA). ClinicalTrials.gov Identifier: NCT 04429763"[URL]
  82. "Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 (COVID-19). ClinicalTrials.gov Identifier: NCT04416139"[URL]
  83. "NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (HOPE). ClinicalTrials.gov Identifier: NCT04315987"[URL]
  84. "Treatment With Human Umbilical Cordderived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)"[URL]
  85. "Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients . ClinicalTrials. gov Identifier: NCT04437823"[URL]
  86. "Clinical Use of Stem Cells for the Treatment of Covid-19. ClinicalTrials.gov Identifier: NCT 04392778"[URL]
  87. "Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19. ClinicalTrials.gov Identifier: NCT04390152"[URL]
  88. "MSCs in COVID-19 ARDS .Clinical Trials.gov Identifier: NCT04371393"[URL]
  89. "Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 (COVIDMES). ClinicalTrials.gov Identifier: NCT04390139"[URL]
  90. "Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard (CIRCA-19). ClinicalTrials.gov Identifier: NCT04400032"[URL]
  91. "ACT-20 in Patients With Severe COVID-19 Pneumonia. ClinicalTrials.gov Identifier: NCT04398303"[URL]
  92. "Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation Clinical-Trials.gov Identifier: NCT04397796"[URL]
  93. "Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19ClinicalTrials.gov Identifier: NCT04389450"[URL]
  94. "A Study of Cell Therapy in COVID-19Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy. ClinicalTrials.gov Identifier:NCT04445220"[URL]
  95. Kim K, "Improved isolation and culture of urine-derived stem cells(USCs)and enhanced production of immune cells from the USC-derived induced pluripotent stem cells", J Clin Med, 9, pp.827~ (2020)
  96. Kim K, "3, 2'-Dihydroxyflavone Improves the proliferation and survival of human pluripotent stem cells and their differentiation into hematopoietic progenitor cells", J Clin Med, 9, pp.669~ (2020)
  97. Tsuchiya A, "Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019(COVID-19)cases", Inflammation and Regeneration, 40, pp.1~6 (2020)
  98. Akkoc T, "COVID-19 and mesenchymal stem cell treatment; mystery or not", Adv Exp Med Biol., pp.1~10 (2020)[DOI]
  99. Pinky, "Mesenchymal stem cell derived exosomes: a nano platform for therapeutics and drug delivery in combating COVID-19", Stem Cell Rev Rep, pp.1~11 (2020)[DOI]
  100. Muraca M, "Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?", J Control Release, 325, pp.135~140 (2020)
  101. O'Driscoll L, "Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment", Drug Discovery Today (2020)[DOI]
  102. Sleem A, "Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy", Curr Res Transl Med (2020)[DOI]
  103. Harrell CR, "Therapeutic Use of Mesenchymal Stem Cell-Derived Exosomes : From Basic Science to Clinics", Pharmaceutics, 12, pp.474~ (2020)
  104. Balachandar V, "COVID-19 : emerging protective measures", Eur Rev Med Pharmacol Sci, 24, pp.3422~3425 (2020)

관련 논문AI추천

Mesenchymal Stem Cell-derived Exosomes: Applications in Cell-free Therapy김진관, 허준석대한임상검사과학회 · 대한임상검사과학회지2018 · 제50권 제4호Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical ReviewDominique Bron, Laurence Lagneaux, Mehdi Najar, Mohammad Krayem, Nathalie Meuleman대한면역학회 · Immune Network2017 · 제17권 제2호Mesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives엄영우, Moon Young Kim, Seong Hee Kang, Soon Koo Baik거트앤리버 소화기연관학회협의회 · Gut and Liver2020 · 제14권 제3호Stem cell exosomes: new hope and future potential for relieving liver fibrosisChong Jin, Hao Jiang, Jinggang Mo, Kunpeng Wang, Lihua Li, Yongjie Liu, Zhiyong Weng대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Lipopolysaccharide로 자극한 RAW 264.7 세포에서 성체줄기세포 유래 엑소좀(exosome)의 면역 조절 효과구나연, 박미정, 변정수, 이지현, 정수경, 조인수, 차상호한국미생물·생명공학회 · 한국미생물·생명공학회지2016 · 제44권 제3호The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the futureAtsunori Tsuchiya, Shuji Terai, Yusuke Watanabe대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제1호

이 간행물의 다른 논문 (7건)

Single-cell and spatial transcriptomics approaches of cardiovascular development and disease김지수, Robert Roth, Siyeon Rhee, 김수지pp. 393-399Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processesBruna Oliveira de Almeida, João Agostinho Machado-Netopp. 413-418Bee venom inhibits the proliferation and migration of cervical-cancer cells in an HPV E6/E7-dependent mannerHyun-Woo Lee, Kyung-Hee Chun, Da-Hyun Kim, Han-Woong Lee, 박현우pp. 419-424Tumor necrosis factor-inducible gene 6 interacts with CD44, which is involved in fate-change of hepatic stellate cells이찬빈, Sihyung Wang, 정영미, Ji-Eun Kimpp. 425-430TCP10L negatively regulates alpha-fetoprotein expression in hepatocellular carcinomaLongjiang Liu, Huan Feng, Long Yu, Jiaxue Wu, Suqin Shen, Wei Supp. 431-436
원문 보기